SEC Form 3: New insider Choong Ingrid claimed ownership of 33,500 shares
$EIGR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 08/30/2023 |
3. Issuer Name and Ticker or Trading Symbol
Eiger BioPharmaceuticals, Inc. [ EIGR ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 31,100(1) | D | |
| Common Stock | 2,400 | I | By Family Trust(2) |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Option (Right to Buy) | (3) | 09/23/2023 | Common Stock | 5,251 | 1.37 | D | |
| Stock Option (Right to Buy) | (3) | 08/28/2026 | Common Stock | 7,490 | 15.89 | D | |
| Stock Option (Right to Buy) | (3) | 03/08/2027 | Common Stock | 13,200 | 11.75 | D | |
| Stock Option (Right to Buy) | (3) | 03/13/2028 | Common Stock | 25,000 | 9.5 | D | |
| Stock Option (Right to Buy) | (3) | 03/20/2029 | Common Stock | 17,500 | 14.31 | D | |
| Stock Option (Right to Buy) | (4) | 09/29/2029 | Common Stock | 10,000 | 10.25 | D | |
| Stock Option (Right to Buy) | (5) | 03/11/2030 | Common Stock | 35,000 | 5.6 | D | |
| Stock Option (Right to Buy) | (6) | 03/11/2031 | Common Stock | 60,000 | 9.99 | D | |
| Stock Option (Right to Buy) | (7) | 07/28/2031 | Common Stock | 17,500 | 8.15 | D | |
| Stock Option (Right to Buy) | (8) | 03/10/2032 | Common Stock | 98,000 | 5.1 | D | |
| Stock Option (Right to Buy) | (9) | 01/25/2033 | Common Stock | 25,750 | 1.37 | D | |
| Stock Option (Right to Buy) | (10) | 02/28/2033 | Common Stock | 98,000 | 1.71 | D | |
| Explanation of Responses: |
| 1. Includes 3,333 shares underlying Restricted Stock Units ("RSUs") award that will vest in three equal annual installments measured from March 12, 2021, and 10,666 shares underlying RSUs award that will vest in three equal annual installments measured from March 11, 2022. |
| 2. These shares are held directly by the Choong-Dragoli Family Trust, for which the Reporting Person serves as co-trustee. |
| 3. These options are fully vested. |
| 4. The option vests in equal installments over 48 months measured from September 30, 2019, subject to the Reporting Person's continuous service as of each such date. |
| 5. The option vests in equal installments over 48 months measured from March 12, 2020, subject to the Reporting Person's continuous service as of each such date. |
| 6. The option vests in equal installments over 48 months measured from March 12, 2021, subject to the Reporting Person's continuous service as of each such date. |
| 7. The option vests in equal installments over 36 months measured from July 29, 2021, subject to the Reporting Person's continuous service as of each such date. |
| 8. The option vests in equal installments over 48 months measured from March 11, 2022, subject to the Reporting Person's continuous service as of each such date. |
| 9. The option vests as to 50% on the first anniversary of the January 26, 2023 grant date, and as to the remaining 50% on June 26, 2024, subject to the Reporting Person's continuous service as of each such date. The option vests in full upon a change in control of the Issuer. |
| 10. The option vests in equal installments over 48 months measured from March 1, 2023, subject to the Reporting Person's continuous service as of each such date. |
| Remarks: |
| Exhibit List: Exhibit 24 - Power of Attorney |
| /s/ James Vollins, Attorney-in-Fact for Ingrid C. Choong | 09/05/2023 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||